Google Scholar
Barbara Bartmeyer1, the HIV-1 Seroconverter cohort and the ClinSurv HIV cohort
D Schmidt, C Kollan, M Stoll, O Hamouda, V Bremer… - 2021
2021
Calculation of Direct Antiretroviral Treatment Costs and Potential Cost Savings by
M Stoll, C Kollan, F Bergmann, J Bogner… - 2011 - academia.edu
2011
Background/Aim of the Study: The study aimed to determine the cost impacts of antiretroviral drugs by analysing a longterm follow-up of direct costs for combined antiretroviral therapy, …
How do generic quotas work? An analysis using HIV infection as an example
…, M Schulz, B Bartmeyer, C Kollan… - …, 2021 - pmc.ncbi.nlm.nih.gov
2021
Hintergrund Die Steuerungsinstrumente der Arzneimittelversorgung in der gesetzlichen Krankenversicherung (GKV) sind schon länger Bestandteil der gesundheitspolitischen …
Estimating Trends in the Proportion of Transmitted and Acquired HIV Drug
D Schmidt, C Kollan, G Fätkenheuer, E Schülter… - 2014 - pdfs.semanticscholar.org
2014
Objective: We assessed trends in the proportion of transmitted (TDR) and acquired (ADR) HIV drug resistance and associated mutations between 2001 and 2011 in the German …
Cooperative sensing in distributed military environment using smart devices
DP Iracleous, A Kollan, D Rigas - researchgate.net
The distributed environment of a military theater can be represented by an aggregate model and be measured by a set of scattered sensors on mobile devices. The state of this system …
Wie wirken Generikaquoten? Eine Analyse am Beispiel der HIV-Infektion
…, G Gradl, M Schulz, B Bartmeyer, C Kollan… - Bundesgesundheitsblatt …, 2021 - Springer
۲ ارجاع2021
Hintergrund Die Steuerungsinstrumente der Arzneimittelversorgung in der gesetzlichen Krankenversicherung (GKV) sind schon länger Bestandteil der gesundheitspolitischen …
CD4-cell counts and presence of AIDS in HIV-positive patients entering specialized care-a comparison of migrant groups in the German ClinSurv HIV Cohort Study …
…, C Santos-Hovener, C Kollan… - BMC Infectious …, 2016 - search.proquest.com
2016
Background Although early presentation to HIV-care is essential to ensure timely initiation of antiretroviral therapy, recent studies have shown that especially migrants present to HIV-…
O423 Risk of new AIDS-defining events in patients with advanced immunodeficiency during suppressive HAART: results from the German ClinSurv cohort
…, C Kreuzberg, M An der Heiden, C Kollan… - Journal of the …, 2008 - Springer
2008
Methods Data of 1,576 treatment-naive patients starting HAART after January 1, 1996 at a CD4 count< 200 cells/μl were followed from the date of full viral suppression until virological …
HIV-Jahresbericht 2025
L Adamíková, M Friebe, K Schön, C Kollan, A Hofmann… - 2026 - edoc.rki.de
2026
Gemäß § 7 Abs. 3 Infektionsschutzgesetz (IfSG) ist der direkte oder indirekte Nachweis einer Infektion mit dem Humanen Immundefizienz-Virus (HIV) nichtnamentlich direkt an das …
O19. 3 Estimate of the Prevalence of Transmitted Drug Resistance (TDR) and Acquired Drug Resistance (ADR) in a HIV Resistance Study of the German ClinSurv-HIV …
B Bartmeyer, D Schmidt, C Kollan… - Sexually Transmitted …, 2013 - sti.bmj.com
2013
Aim To estimate the prevalence of HIV-TDR and ADR in one resistance study of the German ClinSurv-HIV cohort. Method The ClinSurv study is a national open multi-centre long term …